{
    "symbol": "SSKN",
    "quarter": 4,
    "year": 2022,
    "date": "2023-04-01 00:30:06",
    "content": " As a brief recap, this year, we achieved record revenues, acquired and successfully -- commercially launched TheraClearX for acne treatment, launched XTRAC 1.0 Momentum, aesthetic laser device than our standard model, strengthened our leadership team with the addition of John Bagdasarian, Vice President, Professional Relations; and Mike Goodman, Head of International Sales, entered into new international markets, including Israel and Mexico, and continue to raise awareness of our XTRAC and TheraClearX systems at various dermatology conferences. Revenues for the fourth quarter of 2022 were $10.6 million, a 17% increase over the fourth quarter of 2021 and a 13% increase over the third quarter of 2022. Recurring revenues in the fourth quarter were $6.5 million, a 12% increase over the third quarter of 2022. Equipment revenues for the fourth quarter were $4.1 million, an increase of 72% as compared to the $2.3 million for the fourth quarter of 2021 and an increase of 14% as compared to $3.6 million for the third quarter of 2022. For the fourth quarter 2022, non-GAAP gross domestic recurring billings was $5.8 million, a decrease of 6% as compared to $6.1 million in the fourth quarter of 2021 and an increase of 4% as compared to the $5.5 million for the third quarter of 2022. Recurring revenues in 2022 were $23 million, and equipment revenues for the full year were $13.1 million, a 76% increase over 2021. For the full year 2022, non-GAAP gross domestic recurring billings were $22.2 million, a 1% increase over the full year 2021. Total operating expenses in 2022 was $26.4 million, an increase of 8.9% as compared to $24.3 million for the full year 2021."
}